## Neutrophil-to-Lymphocyte Ratio and Insulin Resistance

# **Relationship in Obese Individuals with Normal and**

# **Impaired Glucose Tolerance**

Eyyüp Murat Efendioğlu<sup>1\*</sup> and Mustafa Araz<sup>2</sup>

<sup>1</sup>Gaziantep University, Faculty of Medicine, Department of Internal Medicine, Division of Geriatric Medicine, Gaziantep, Turkey.

<sup>2</sup>Gaziantep University, Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Gaziantep, Turkey.

#### Abstract

Neutrophil-to-lymphocyte ratio (NLR) may be a predictor of glucose intolerance in obese individuals and may be useful in the early detection of glucose intolerance. In this study, we aimed to investigate the relationship between NLR and insulin resistance (IR) in obese individuals with normal and impaired glucose tolerance. Seventy-three obese patients and 27 healthy controls were included in this study. The participants' sociodemographic anthropometric measurements (height, body weight, and waist characteristics, circumference), fasting plasma glucose, oral glucose tolerance test (OGTT), insulin, HbA1c, total cholesterol, triglyceride, high-density lipoprotein (HDL), thyroid-stimulating hormone (TSH), complete blood count, and C-reactive protein (CRP) results were obtained from the files. Homeostasis Model Assessment Insulin Resistance (HOMA-IR) values were calculated. The mean age of the 100 patients was 36.4±10.5 years, and 59.0% were female. There was a statistically significant positive correlation between the HOMA-IR and the BMI (r = 0.457, p = 0.000), HbA1c (r = 0.359, p = 0.000), CRP (r = 0.444, p = 0.000), and waistcircumference (r = 0.478, p = 0.000). There was no statistically significant difference between the obese and healthy control groups in terms of NLR. However, there was a significant difference in NLR, CRP, and neutrophil counts between the high HOMA-IR and normal HOMA-IR groups. In our study, neutrophil counts and CRP were determined to be higher among obese individuals than among healthy individuals. The NLR was increased significantly among patients with IR.

Key words: Obesity, Insulin resistance, Neutrophil-to-lymphocyte ratio.

<sup>\*</sup>Corresponding Author: Eyyüp Murat Efendioğlu, E-mail: <u>eefendioglu@gmail.com</u>. Tel: +90 342 341 66 89. ORCID ID: 0000-0002-3257-7352.

## Introduction

Obesity is an epidemic worldwide and increases the risk for many diseases, particularly insulin resistance (IR) and type 2 diabetes mellitus (T2DM). Obesity is considered a state of chronic and lowgrade inflammation as well as increased oxidative stress (1). The relationship between chronic low-grade inflammation, IR, and other obesity-associated metabolic disturbances has become increasingly recognized (2).

Insulin resistance is common in patients with chronic inflammatory diseases characterized by unbalanced secretion of proinflammatory and anti-inflammatory cytokines. Measurement of IR provides an early and strong prediction of T2DM (3). The precise molecular effect leading to IR is not yet understood, but several studies have shown the relationship between systemic inflammation and IR (4, 5).

Recent studies have shown that combined indices derived from whole blood counts, such as neutrophil-to-lymphocyte ratio (NLR), are good indicators of systemic inflammation and immune status and are widely used in clinical diagnosis and prognosis evaluation. Generally, both acute and chronic inflammation cause elevated NLR through relative neutrophilia and lymphopenia. Neutrophil-to-lymphocyte ratio is a dynamic state and influenced by inflammatory cytokines and endocrine effects of the hypothalamic-pituitary axis (6, 7).

Previous studies indicate that an elevated NLR is associated with cardiovascular diseases (acute coronary syndrome outcomes, heart failure, and atrial fibrillation) (8-10). Also, NLR has been recently defined as a novel potential inflammation marker in many cancers and inflammatory diseases (11-13).

Neutrophil-to-lymphocyte Ratio and Insulin Resistance In a recent study, it was stated that NLR could be used as a marker for obese individuals with high IR, but the lack of measurement regarding other inflammatory markers such as C-reactive protein and demographic data (eg, waist circumference) stood out as important limitations in that study (14). Neutrophil-to-lymphocyte ratio may be a predictor of glucose intolerance in obese

predictor of glucose intolerance in obese individuals and may be useful in the early detection of glucose intolerance. In this study, we aimed to evaluate the relationship between NLR and IR in obese individuals with normal and impaired glucose tolerance.

## Materials and Methods

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval for the study was granted by the Gaziantep University Clinical Research Ethics Committee with decision number 2015/330. A total of 100 outpatients between the ages of 18-65 who applied to our Endocrinology and Metabolism Outpatient Clinics of the Department of Internal Medicine were included in this study from December 2014 to December 2015 and the files of the patients were scanned retrospectively. A body-mass index (BMI) of 18.5 to 25  $kg/m^2$  was considered normal, and a BMI of 30 kg/m<sup>2</sup> and higher was considered obese.

The participants were divided into 3 groups:

Group 1: Obese patients with normal glucose tolerance (NGT) (BMI  $\geq$ 30 kg/m<sup>2</sup>, n=43).

Group 2: Obese patients with impaired glucose tolerance (IGT) (BMI  $\geq$ 30 kg/m<sup>2</sup>, n=30).

Group 3: Healthy control group with impaired fasting glucose (normal BMI and NGT, n=27).

Major exclusion criteria were infectious conditions, malignancies, inflammatory rheumatic diseases, pregnancy, chronic kidney disease, acute and chronic liver disease. The participants' sociodemographic characteristics, anthropometric measurements (height, body weight, and waist circumference), fasting plasma glucose, OGTT, insulin, HbA1c, total cholesterol, triglyceride, HDL, TSH, complete blood count, and CRP results were obtained from the files. Neutrophil-to-lymphocyte ratio was calculated as the simple ratio between the absolute neutrophil and lymphocyte count, which were both obtained from the same automated blood sample. Fasting insulin was measured by enzyme-linked and immunosorbent IR assay, was calculated using the Homeostatic Model for Insulin Assessment Resistance (HOMA-IR). Homeostatic Model Assessment for Insulin Resistance was calculated using the equation: HOMA-IR=Fasting insulin ( $\mu$ U/mL) x Fasting glucose (mg/dL) /405 and a HOMA-IR value of >2.5 was considered IR.

## Statistical analysis

The normality of distribution of continuous variables was tested by the Kolmogorov

Neutrophil-to-lymphocyte Ratio and Insulin Resistance Smirnov test. The independent samples ttest was used to compare two normally distributed independent groups, Mann-Whitney U-test to compare two nonnormally distributed independent groups, and Kruskall Wallis test was used to compare three non-normally distributed independent groups. Relationships between categorical variables were tested with chisquare analysis, and relationships between numerical variables were tested with Spearman's rank correlation coefficient. SPSS for Windows version 22.0 package program was used for statistical analysis and p<0.05 was considered statistically significant.

## Results

The mean age of the 100 was  $36.4 \pm 10.5$ patients years, and 59.0% were female. Participants' socio-demographic characteristics, anthropometric measurement results, and laboratory analysis results are shown in Table 1. CRP and neutrophil counts were significantly higher in the IGT and NGT obese groups compared to the healthy control group ( $p = \langle 0.001 \text{ and } p = 0.007$ , respectively). NLR was found to be higher in individuals with high HOMA-IR compared to those with normal HOMA-IR (p = 0.050) (Table 2). There was a statistically significant positive correlation between the HOMA-IR and the BMI (r =0.457, p = 0.000), HbA1c (r = 0.359, p =(0.000), CRP (r = 0.444, p = 0.000), and waist circumference (r = 0.478, p = 0.000) (Table 3).

#### Neutrophil-to-lymphocyte Ratio and Insulin Resistance

		analysis results.			-
	IGT obese (n=30)	NGT obese (n=43)	Healthy control (n=27)	р	Total (n=100)
Gender					
Female	17 (56.7%)	26 (60.5%)	16 (59.3%)	0.040	59 (59.0%)
Male	13 (43.3%)	17 (39.5%)	11 (40.7%)	0.948	41 (41.0%)
Age(years) <sup>#</sup>	41.5±9.3*	34.3±11.8	34.1±7.3	0.005*	36.4±10.5
BMI (kg/m <sup>2</sup> ) <sup>#</sup>	37.3±6.5*	34.4±4.4*	24.0±2.7*	< 0.001*	32.4±7.1
Waist circumference (cm) <sup>#</sup>	121.1±11.9*	114.7±15.4*	84.9±12.3*	< 0.001*	108.5±20.0
Insulin (mU/ml) <sup>†</sup>	13.6	9.9	6.0*	<0.001*	9.6
HbA1c (%) <sup>†</sup>	6.0*	5.5	5.4	0.001*	5.6
HOMA-IR <sup>†</sup>	3.4	2.2	1.3*	<0.001*	2.2
Total cholesterol (mg/dl) $^{\dagger}$	209	197	200	0.662	199
Triglyceride (mg/dl) <sup>†</sup>	157	151	117	0.082	146
HDL (mg/dl) <sup>†</sup>	49	45*	53*	0.007*	48
TSH (uIU/mL) <sup>†</sup>	2.3	2.5	1.5*	<0.001*	2.1
CRP (mg/dl) <sup>†</sup>	4.6	4.1	1.2*	<0.001*	2.9
Neutrophil $(10^{3/}\mu L)^{\dagger}$	4745*	4310	3710*	0.007*	4245
Lymphocyte $(10^{3/}\mu L)^{\dagger}$	2645	2500	2200	0.076	2495
NLR <sup>†</sup>	1.78	1.53	1.65	0.880	1.63

Table 1: Participants'	ocio-demographic characteristics, anthropometric measurement results, and laborator	y

\* $p\leq0.05$ . \*Data are presented as mean $\pm$ SD; †Data are presented as median; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; BMI, body mass index; HOMA-IR, the homeostasis model assessment-estimated insulin resistance; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio.

#### E. M. Efendioğlu and M. Araz

Neutrophil-to-lymphocyte Ratio and Insulin Resistance

	HOMA-IR <2.5 (n=56)	HOMA-IR ≥2.5 (n=44)	р	Total (n=100)
Gender				
Female	36 (64.3%)	23 (52.3%)		59 (59.0%)
Male	20 (35.7%)	21 (47.7%)	0.306	41 (41.0%)
Age(years) <sup>#</sup>	34.3±10.2	39.1±10.3	0.024*	36.4±10.5
<b>BMI</b> (kg/m <sup>2</sup> ) <sup>#</sup>	30.0±6.3	35.5±7.0	< 0.001*	32.4±7.1
Waist circumference (cm) <sup>#</sup>	100.1±19.0	118.2±17.0	<0.001*	108.5±20.0
Insulin (mU/ml) $^{\dagger}$	6.7	16.9	< 0.001*	9.6
HbA1c $(\%)^{\dagger}$	5.4	5.8	<0.001*	5.6
Total cholesterol (mg/dl) $^{\dagger}$	196	209	0.158	199
Triglyceride (mg/dl) $^{\dagger}$	124	174	0.002*	146
HDL (mg/dl) <sup><math>\dagger</math></sup>	50	45	0.045*	48
TSH (uIU/mL) <sup><math>\dagger</math></sup>	1.9	2.3	<0.001*	2.1
CRP (mg/dl) <sup>†</sup>	1.9	4.5	<0.001*	2.9
Neutrophil $(10^{3/}\mu L)^{\dagger}$	3930	4765	0.005*	4245
Lymphocyte $(10^{3/}\mu L)^{\dagger}$	2505	2495	0.721	2495
$\mathbf{NLR}^\dagger$	1.51	1.84	0.050*	1.63

\* $p \le 0.05$ . #Data are presented as mean $\pm$ SD; †Data are presented as median; BMI, body mass index; HOMA-IR, the homeostasis model assessment-estimated insulin resistance; CRP, C-reactive protein; NLR, neutrophil-to-lymphocyte ratio.

Neutrophil-to-lymphocyte Ratio and Insulin Resistance

Age         r         0.302         0.401         0.102         0.364         0.082         -0.           BMI         r         0.302         0.401         0.102         0.364         0.082         -0.           BMI         r         0.302         0.000*         0.313         0.000*         0.415         0.           BMI         r         0.302         0.847         0.420         0.339         0.588         -0.           Waist         r         0.401         0.847         0.400*         0.000*         0.001*         0.000*         0.           Gircumference         p         0.000*         0.000*         0.000*         0.000*         0.000*         0.           Insulin         r         0.102         0.420         0.459         0.322         0.394         0.           HbA1c         r         0.364         0.339         0.279         0.322         0.428         -0.           r         0.364         0.339         0.279         0.322         0.428         -0.           HbA1c         p         0.364         0.339         0.279         0.322         0.428         -0.           p         0.415         0			100105.	egoricai vai				Lable 3		
Age $p$ $0.002^*$ $0.000^*$ $0.313$ $0.000^*$ $0.415$ $0.$ BMIr $0.302$ $0.847$ $0.420$ $0.339$ $0.588$ $-0.$ $p$ $0.002^*$ $0.000^*$ $0.000^*$ $0.001^*$ $0.000^*$ $0.000^*$ Waistr $0.401$ $0.847$ $0.459$ $0.279$ $0.519$ $0.000^*$ Circumference $p$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ Insulinr $0.102$ $0.420$ $0.459$ $0.322$ $0.394$ $0.000^*$ <th>ILR HOMA- IR</th> <th>NLR</th> <th>CRP</th> <th>HbA1c</th> <th>Insulin</th> <th></th> <th>BMI</th> <th>Age</th> <th></th> <th></th>	ILR HOMA- IR	NLR	CRP	HbA1c	Insulin		BMI	Age		
p $0.002^*$ $0.000^*$ $0.313$ $0.000^*$ $0.415$ $0.$ BMIr $0.302$ $0.847$ $0.420$ $0.339$ $0.588$ $-0.$ p $0.002^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.001^*$ $0.000^*$ $0.$ Waistr $0.401$ $0.847$ $0.459$ $0.279$ $0.519$ $0.$ circumferencep $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ Insulinr $0.102$ $0.420$ $0.459$ $0.322$ $0.394$ $0.$ HbA1cr $0.364$ $0.339$ $0.279$ $0.322$ $0.428$ $-0.$ $p$ $0.000^*$ $0.001^*$ $0.000^*$ $0.001^*$ $0.000^*$ $0.000^*$ $0.$ CRPr $0.082$ $0.588$ $0.519$ $0.394$ $0.428$ $0.$ $p$ $0.415$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$	.064 0.148	-0.064	0.082	0.364	0.102	0.401	0.302		r	A
BMI $p$ 0.002*         0.000*         0.001*         0.000*         0.00*         0.0*         0.0*         0.0*         0.0	.529 0.141	0.529	0.415	0.000*	0.313	0.000*	0.002*		р	Age
p $0.002^*$ $0.000^*$ $0.000^*$ $0.001^*$ $0.000^*$ $0.$	.012 0.457	-0.012	0.588	0.339	0.420	0.847		0.302	r	DMI
circumference $p$ 0.000*	.903 0.000*	0.903	0.000*	0.001*	0.000*	0.000*		0.002*	р	BMI
Insulinr0.1020.4200.4590.3220.3940. $p$ 0.3130.000*0.000*0.001*0.000*0.HbA1cr0.3640.3390.2790.3220.428-0. $p$ 0.000*0.001*0.005*0.001*0.000*0.CRPr0.0820.5880.5190.3940.4280. $p$ 0.4150.000*0.000*0.000*0.000*0.	.007 0.478	0.007	0.519	0.279	0.459		0.847	0.401	r	Waist
Insulin $p$ 0.313         0.000*         0.000*         0.001*         0.000*         0.           HbA1c         r         0.364         0.339         0.279         0.322         0.428         -0. $p$ 0.000*         0.001*         0.005*         0.001*         0.000*         0. $r$ 0.082         0.588         0.519         0.394         0.428         0. $p$ 0.415         0.000*         0.000*         0.000*         0.000*         0.	.944 0.000*	0.944	0.000*	0.005*	0.000*		0.000*	0.000*	р	circumference
p $0.313$ $0.000^*$ $0.000^*$ $0.001^*$ $0.000^*$ $0.$ HbA1cr $0.364$ $0.339$ $0.279$ $0.322$ $0.428$ $-0.$ p $0.000^*$ $0.001^*$ $0.005^*$ $0.001^*$ $0.000^*$ $0.000^*$ $0.$ CRPr $0.082$ $0.588$ $0.519$ $0.394$ $0.428$ $0.$ p $0.415$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$	.133 0.980	0.133	0.394	0.322		0.459	0.420	0.102	r	Inculin
HbA1c $p$ 0.000*0.001*0.005*0.001*0.000*0.CRPr0.0820.5880.5190.3940.4280. $p$ 0.4150.000*0.000*0.000*0.000*0.	.188 0.000	0.188	0.000*	0.001*		0.000*	0.000*	0.313	р	msum
p $0.000^*$ $0.001^*$ $0.005^*$ $0.001^*$ $0.000^*$ $0.000^*$ r $0.082$ $0.588$ $0.519$ $0.394$ $0.428$ $0.$ p $0.415$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$ $0.000^*$	.037 0.359	-0.037	0.428		0.322	0.279	0.339	0.364	r	IIb A 1 o
<b>CRP</b> $p$ $0.415$ $0.000*$ $0.000*$ $0.000*$ $0.000*$ $0.000*$	.718 0.000	0.718	0.000*		0.001*	0.005*	0.001*	0.000*	р	HDAIC
p 0.415 0.000* 0.000* 0.000* 0.000* 0.000* 0.	.148 0.444	0.148		0.428	0.394	0.519	0.588	0.082	r	CDD
r 0.064 0.012 0.007 0.122 0.027 0.148	.142 0.000	0.142		0.000*	0.000*	0.000*	0.000*	0.415	р	CNF
NLR	0.126		0.148	-0.037	0.133	0.007	-0.012	-0.064	r	NI D
<i>p</i> 0.529 0.903 0.944 0.188 0.718 0.142	0.212		0.142	0.718	0.188	0.944	0.903	0.529	р	
r 0.148 0.457 0.478 0.980 0.359 0.444 0.	126	0.126	0.444	0.359	0.980	0.478	0.457	0.148	r	
HOMA-IR $p$ 0.141 0.000* 0.00	212	0.212	0.000*	0.000*	0.000*	0.000*	0.000*	0.141	р	ΠΟΙΛΙΑ-ΙΚ

**Table 3:** Correlation analysis results between categorical variables.

r: Spearman rank correlation coefficient. \*Significant at 0.01 level. BMI, body mass index; CRP, C-reactive protein (mg/dl); NLR, neutrophil-to-lymphocyte ratio; HOMA-IR, the homeostasis model assessment-estimated insulin resistance.

#### Discussion

Our study has shown that IR, BMI, CRP, neutrophil, and waist circumference were significantly higher in the obese patients with IGT and NGT compared to the healthy control group. There was no statistically significant difference for the NLR between groups. However, we observed that both NLR and neutrophil count increased as the IR level increased. Experimental studies have demonstrated a link between chronic inflammation and IR through mechanisms that include obesity and atherosclerosis (15)(16). Obesity is also associated with inflammation. A previous study revealed that obesity, defined by BMI and waist circumference, was associated with inflammation (17).

Studies evaluating the relationship between NLR and obesity have shown that other markers such as CRP are more closely associated with obesity, and NLR tends to increase in obese patients (18)(19)(20). Previous studies illustrated that NLR could be a potential surrogate marker of systemic inflammation with its ability to predict CRP levels (21)(22). However, some studies opposed these observations. A study conducted in Turkey has reported that NLR was similar in obese and nonobese individuals (14). Also in a study, NLR was not found to be a good indicator of inflammation, while hs-CRP and leukocytes were more useful biomarkers to indicate inflammation in non-diabetic patients with obesity (23).

In one study, NLR was found to be higher in individuals with IGT, newly diagnosed with diabetes by OGTT, and previously diagnosed with diabetes compared to individuals with NGT (24). Additionally, a study showed that NLR is a risk factor for IR with DM (25).

Imtiaz et al. demonstrated that systemic inflammation measured by NLR is closely associated with prevalent chronic conditions such as hypertension and (13).Another study diabetes has demonstrated the association of NLR with glucose intolerance and IR severity (26).

According to our results, we observed that HOMA-IR and HbA1c values were higher among the obese patient group with IGT than the obese patient group with NGT, while the NLR was similar between the two groups.

The present study had several limitations. preliminary study involved This а retrospective analysis of a small population from a single institution. Despite these limitations, this study has some strengths. participants We included without that comorbidities could affect inflammatory parameters, thereby ensuring more homogeneous groups of participants. In addition, combining anthropometric measurements and laboratory measurements was one of the strengths of our study.

In conclusion, neutrophil counts and CRP were determined to be higher among obese individuals than among healthy individuals in our study. Also, NLR, neutrophil counts, and CRP were found to be significantly higher in individuals with IR compared to individuals without IR.

Studies with prospective designs and multiple NLR measurements may provide more robust evidence to demonstrate the role of NLR as a marker of subclinical Neutrophil-to-lymphocyte Ratio and Insulin Resistance inflammation and a predictor of prediabetes risk.

**Conflict of interest:** The authors report no actual or potential conflicts of interest. The authors confirm independence from the sponsors, the content of the article has not been influenced by the sponsors.

Acknowledgment: Authors contributed equally to the study. No external or intramural funding was received.

### References

**1.** Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011 Jun;121(6):2111–7.

**2.** Heilbronn LK, Campbell L V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008;14(12):1225–30.

**3.** Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989 Aug;321(6):337–43.

**4.** Zimmet PZ, McCarty DJ, de Courten MP. The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome. J Diabetes Complications. 1997;11(2):60–8.

**5.** Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793–801.

6. Zulfic Z, Weickert CS, Weickert TW, et al. Neutrophil-lymphocyte ratio - a simple, accessible measure of inflammation, morbidity and prognosis in psychiatric disorders? Australas psychiatry Bull R Aust New Zeal Coll Psychiatr. 2020 Aug;28(4):454–8.

**7.** Faria SS, Fernandes PCJ, Silva MJB, et al. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016;10:702.

**8.** Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008 Sep;102(6):653–7.

**9.** Benites-Zapata VA, Hernandez AV, Nagarajan V, et al. Usefulness of neutrophil-tolymphocyte ratio in risk stratification of patients with advanced heart failure. Am J Cardiol. 2015 Jan;115(1):57–61.

10. Shao Q, Chen K, Rha S-W, et al.

Usefulness of Neutrophil/Lymphocyte Ratio as a Predictor of Atrial Fibrillation: A Meta-analysis. Arch Med Res. 2015 Apr;46(3):199–206.

**11.** Tsai P-L, Su W-J, Leung W-H, et al. Neutrophil-lymphocyte ratio and CEA level as prognostic and predictive factors in colorectal cancer: A systematic review and meta-analysis. J Cancer Res Ther. 2016;12(2):582–9.

**12.** Dimitriou N, Felekouras E, Karavokyros I, et al. Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. BMC Cancer. 2018 Dec;18(1):1202.

**13.** Imtiaz F, Shafique K, Mirza SS, et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012 Jan;5(1):2.

**14.** Karakaya S, Altay M, Kaplan EF, et al. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity. Turkish J Med Sci. 2019 Feb;49(1):245–8.

**15.** Xu H, Barnes GT, Yang Q, Tan G, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003 Dec;112(12):1821– 30.

**16.** Rajwani A, Cubbon RM, Wheatcroft SB. Cell-specific insulin resistance: implications for atherosclerosis. Diabetes Metab Res Rev. 2012 Nov;28(8):627–34.

**17.** Ellulu MS, Patimah I, Khaza'ai H, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017 Jun;13(4):851–63.

**18.** Demir AD, Durmaz ZH, Özkan T, et al. The ratio of neutrophil lymphocytes and CRP comparison in young obese individuals. Biomed Res, 2017 28(28), 7486-90.

**19.** Furuncuoğlu Y, Tulgar S, Dogan AN, et al.

Neutrophil-to-lymphocyte Ratio and Insulin Resistance How obesity affects the neutrophil/lymphocyte and platelet/lymphocyte ratio, systemic immuneinflammatory index and platelet indices: a retrospective study. Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1300–6.

**20.** Aydin M, Yilmaz A, Donma MM, et al. Neutrophil/lymphocyte ratio in obese adolescents. North Clin Istanbul. 2015;2(2):87–91.

**21.** Angkananard T, Anothaisintawee T, McEvoy M, et al. Neutrophil Lymphocyte Ratio and Cardiovascular Disease Risk: A Systematic Review and Meta-Analysis. Biomed Res Int. 2018;2018:2703518.

**22.** Oh BS, Jang JW, Kwon JH, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013 Feb;13:78.

**23.** Bahadır A, Baltacı D, Türker Y, et al. Is the neutrophil-to-lymphocyte ratio indicative of inflammatory state in patients with obesity and metabolic syndrome? Anatol J Cardiol. 2015 Oct;15(10):816–22.

**24.** Mertoglu C, Gunay M. Neutrophil-Lymphocyte ratio and Platelet-Lymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus. Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S127–31.

**25.** Lou M, Luo P, Tang R, et al. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr Disord. 2015 Mar;15:9.

**26.** Shiny A, Bibin YS, Shanthirani CS, et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technol Ther. 2014 Aug;16(8):524–30.